Table 1.
Patient characteristics
| All (n = 46) |
SCC (n = 41) |
Adenocarcinoma (n = 4) |
NEC (n = 1) |
||
|---|---|---|---|---|---|
| Age (years) |
Median (range) ≥ 75 |
81 (57–93) 37 (80.4%) |
81 (57–93) 33 (80.5%) |
86 (72–88) 3 (75%) |
86 1 |
| Sex | Male | 39 (84.8%) | 35 (85.4%) | 3 (75%) | 1 |
| BMI, kg/m2 | Median (range) | 18.5 (12.8–26.8) | 18.5 (12.8–26.8) | 19.3 (14.7–24.2) | 25.0 |
| ECOG PS |
2 3 4 |
25 (54.3%) 16 (34.8%) 5 (10.9%) |
24 (58.5%) 12 (29.3%) 5 (12.2%) |
1 (25%) 3 (75%) 0 |
0 1 0 |
| Comorbidity index |
0 1 ≥ 2 |
20 (43.5%) 9 (19.6%) 17 (37.0%) |
17 (41.5%) 8 (19.5%) 16 (39.0%) |
3 (75%) 0 1 (25%) |
0 1 0 |
| Clinical T stage* |
cT3 cT4a cT4b |
21 (45.7%) 9 (19.6%) 16 (34.8%) |
20 (48.8%) 6 (14.6%) 15 (36.6%) |
1 (25%) 3 (75%) 0 |
0 0 1 |
| Clinical N stage* |
N0 N1 N2 N3 |
10 (21.7%) 22 (47.8%) 10 (21.7%) 4 (8.7%) |
8 (19.5%) 20 (48.8%) 9 (22.0%) 4 (9.8%) |
2 (50%) 1 (25%) 1 (25%) 0 |
0 1 0 0 |
| Clinical M stage* |
M0 M1 |
23 (50.0%) 23 (50.0%) |
23 (56.1%) 18 (43.9%) |
0 4 (100%) |
0 1 |
| Clinical stage* |
III IVA IVB |
11 (23.9%) 12 (26.1%) 23 (50.0%) |
11 (26.8%) 12 (29.3%) 18 (43.9%) |
0 0 4 (100%) |
0 0 1 |
| Dysphagia score |
2 3 4 |
19 (41.3%) 14 (30.4%) 13 (28.3%) |
17 (41.5%) 12 (29.3%) 12 (29.3%) |
1 (25%) 2 (50%) 1 (25%) |
1 0 0 |
| Borrmann classification |
1 2 3 4 |
4 (8.7%) 25 (54.3%) 13 (28.3%) 4 (8.7%) |
4 (9.8%) 24 (58.5%) 12 (29.3%) 1 (2.4%) |
0 0 1 (25%) 3 (75%) |
0 1 0 0 |
| Primary tumor length, cm | Median (range) | 7.0 (3.0–19.0) | 7.0 (3.0–19.0) | 5.5 (3.0–8.0) | 10.0 |
| Metastatic site |
Lymph node Liver Lung Peritoneal |
38 (82.6%) 1 (2.2%) 7 (15.2%) 3 (6.5%) |
35 (85.4%) 1 (2.4%) 6 (14.6%) 1 (2.4%) |
2 (50%) 0 1 (25%) 2 (50%) |
1 0 0 0 |
| Number of metastatic sites |
0 1 ≥ 2 |
5 (10.9%) 30 (65.2%) 11 (23.9%) |
5 (12.2%) 27 (65.9%) 9 (22.0%) |
0 2 (50%) 2 (50%) |
0 1 0 |
| Primary tumor location |
Upper thoracic Middle thoracic Lower thoracic GEJ |
7 (15.2%) 22 (47.8%) 12 (26.1%) 5 (10.9%) |
7 (17.1%) 21 (51.2%) 12 (29.3%) 1 (2.4%) |
0 0 0 4 (100%) |
0 1 0 0 |
| Alb (g/dL) | median (range) | 3.7 (1.5–4.3) | 3.7 (1.7–4.3) | 3.4 (1.5–4.3) | 3.7 |
| CRP (mg/dL) | median (range) | 0.72 (0.1–19.6) | 0.72 (0.1–19.6) | 1.36 (0.1–9.3) | 0.2 |
| GPS |
0 1 2 |
26 (56.5%) 7 (15.2%) 13 (28.3%) |
23 (56.1%) 7 (17.1%) 11 (26.8%) |
2 (50%) 0 2 (50%) |
1 0 0 |
*Cancer staging followed the Union for International Cancer Control 8th edition guidelines. SCC: squamous cell carcinoma; NEC: neuroendocrine carcinoma; BMI: body mass index; ECOG PS: Eastern Cooperative Oncology Group performance status; GEJ: gastro-esophageal junction; Alb: serum albumin; CRP: serum C-reactive protein; GPS: Glasgow Prognostic Score